Fig. 2
5-FU increases the expression of CCL20 in CRC. a Relative expression of related chemokines in SW620 cells treated with chemotherapy [5-FU (2 μg/ml), L-OHP (10 μg/ml), 5-FU (2 μg/ml) + L-OHP (10 μg/ml)] was analyzed by qPCR. b Log2 fold changes in related chemokine expression of SW620 cells treated with 5-FU compared to the control using a multiplex assay. The supernatant was pooled from three experiments. c Log2 fold changes in related chemokine expression of tumor tissues using multiplex assay for one CRC patient before and after Folfox treatment. The serum was pooled from three patients. d Graph based on the above results (A-C), showing that CCL20 was the key and dominant factor in the altered chemokine expression before and after chemotherapy, especially after 5-FU treatment. A-results from a, B-results from b, C-results from c. e Relative expression of CCL20 in SW620 and DLD-1 cells treated with different doses of 5-FU (μg/ml) at different timepoints (left) was analyzed by qPCR. Relative expression of CCL20 in SW620 and DLD-1 cells treated with the 5-FU concentration at which the most significant change occurs (2 μg/ml for SW620, 50 μg/ml for DLD-1) at different timepoints (right). f Concentration of CCL20 (pg/ml) in supernatants of SW620 cells with or without 5-FU (10 μg/ml) treatment was measured by ELISA. *P < 0.05, **P < 0.01, ***P < 0.001